Corrigendum to “Methylprednisolone pulse therapy for critically ill patients with COVID-19: a cohort study”
Article information
Acute Crit Care. 2023;38(2):249-249
Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu, Korea
Corresponding author Eun Jin Kim Department of Internal Medicine, Daegu Catholic University Medical Center, 33 Duryugongwon-ro 17-gil, Nam-gu, Daegu 42472, Korea Tel: +82-53-650-4274 Fax: +82-53-650-4942 Email:
ejkim77@cu.ac.kr
Acute and Critical Care 2023;38:57-67
https://doi.org/10.4266/acc.2022.00941
In the article entitled “Methylprednisolone pulse therapy for critically ill patients with COVID-19: a cohort study,” some data of was incorrectly presented. The correct is as follows.
Treatment and prognosis in critical or severe COVID-19 cases with control and pulse steroid groups
Article information Continued
Copyright © 2023 The Korean Society of Critical Care Medicine
Table 3.
Treatment and prognosis in critical or severe COVID-19 cases with control and pulse steroid groups
Variable |
Control steroid (n=14) |
Pulse steroid (n=30) |
Total (n=44) |
P-value |
High flow nasal cannula oxygen |
14 (100) |
29 (96.7) |
43 (97.7) |
0.490 |
Mechanical ventilation |
4 (28.6) |
6 (20.0) |
10 (22.7) |
0.527 |
Duration of mechanical ventilation (day) |
18 (11–33) |
8 (4–10) |
10 (6–8) |
0.063 |
Other treatmenta)
|
1 (7.1) |
3 (10.0) |
4 (9.1) |
0.759 |
Prone positionb)
|
7 (50.0) |
21 (70.0) |
28 (63.6) |
0.199 |
In-hospital mortality |
6 (42.9) |
7 (23.3) |
13 (29.5) |
0.186 |
In-hospital mortality among moderate and mild ARDS groups |
4 (44.4) |
2 (13.3) |
6 (25.0) |
0.088 |
In-hospital mortality among severe ARDS group |
2 (40.0) |
5 (33.3) |
7 (35.0) |
0.933 |
28-Day mortality |
5 (35.7) |
7 (23.3) |
12 (27.3) |
0.390 |
Cause of death |
|
|
|
0.255 |
Respiratory failure |
4 (28.6) |
5 (16.7) |
9 (20.5) |
|
Hepatic failure |
2 (14.3) |
0 |
2 (4.5) |
|
Arrhythmia |
0 |
1 (3.3) |
1 (2.3) |
|
Renal failure |
0 |
1 (3.3) |
1 (2.3) |
|
Length of hospital stay (day) |
14 (12–24) |
11 (9–16) |
11 (8–17) |
0.039d)
|
Complication after steroid use |
1 (7.1) |
3 (9.9) |
4 (9.0) |
0.295 |
Uncontrolled hyperglycemia |
0 |
2 (6.7) |
2 (4.8) |
Othersc)
|
1 (7.1) |
1 (3.3) |
2 (4.8) |